Nippon Kayaku Co., Ltd.
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
17%
2 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
Role: collaborator
Study of NK012 in Patients With Refractory Solid Tumors
Role: lead
A Phase III Study of NK105 in Patients With Breast Cancer
Role: lead
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Role: lead
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Role: lead
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
Role: lead
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
Role: lead
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Role: lead
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
Role: lead
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection
Role: lead
A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer
Role: lead
Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer
Role: lead
All 12 trials loaded